Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Coeptis Therapeutics Holdings Inc COEP

Healthcare Biotechnology


NDAQ:COEP - Post by User

Coeptis Therapeutics Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Post by MasterJediJazz2on Jan 16, 2025 1:42pm
17 Views
Post# 36407539

$COEP Dave Mehalick, Chairman, President & CEO of Coeptis

$COEP Dave Mehalick, Chairman, President & CEO of Coeptis
$COEP Dave Mehalick, Chairman, President & CEO of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), discusses the company's innovative approaches in cell therapy, highlighting their focus on making such treatments more universally accessible. 
@coeptistx
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities